Administrative Resolution No. (90) of 2019
Approving the Charges for Laboratory Testing
Services
Provided by the Dubai Health Authority[1]
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
The Director General of the Dubai Health
Authority,
After perusal of:
Law No. (14) of 2009 Concerning the Pricing of Government Services in the
Emirate of Dubai and its amendments;
Law No. (32) of 2015 Concerning the Official Gazette of the Government
of Dubai;
Law No. (1) of 2016 Concerning the Financial Regulations of the
Government of Dubai;
Law No. (6) of 2018 Concerning the Dubai Health Authority (the “DHA");
Decree No. (9) of 2012 Approving a Pricing Method for Dubai Health
Authority Services;
Decree No. (17) of 2018 Establishing the Corporations Affiliated to the
Dubai Health Authority
and Determining their Functions;
Decree No. (18) of 2018 Appointing the Director General of the Dubai
Health Authority;
Executive Council Resolution No. (18) of 2018 Approving the
Organisational Structure of the Dubai Health Authority;
Administrative Resolution No. (148) of 2014 Concerning Health Service Fees;
Administrative Resolution No. (210) of 2018 Concerning the Pricing of
Laboratory Tests Conducted at the Dubai Health Authority Laboratories; and
The letter of the Department of Finance of the Government of Dubai, dated 6 November 2018, approving new charges for laboratory
testing services provided by the Dubai Health Authority,
Does hereby issue this Resolution.
Pursuant to
this Resolution, the charges for laboratory testing services provided by the
DHA laboratories,
as stated in the Schedule attached hereto, are approved.
All
Organisational Units of the DHA, each within its own powers, must take the necessary action to implement this
Resolution.
The cited
Administrative Resolution No. (210) of 2018 Concerning the Pricing of
Laboratory Tests Conducted at the Dubai Health Authority Laboratories is hereby
repealed. Any legislative
provision or other resolution will also be repealed to the extent that
it contradicts the provisions of this Resolution.
This
Resolution comes into force on 25 December 2018, and will be published in the
Official Gazette.
Humaid Al Qatami
Director General
Issued in Dubai on 4 July 2019
Corresponding to 1 Thu al-Qidah
1440 A.H.
|
SN |
Billing
Code / Service Code |
Service
Description |
Proposed
Charges |
|
1 |
81378 |
HLA Class I and II typing, high resolution (ie,
alleles or allele groups), HLA-A, -B, -C, and -DRB1 |
3,000.00 |
|
2 |
81379 |
HLA Class I typing, high resolution (ie, alleles
or allele groups); complete (ie, HLA-A, -B, and -C) |
2,000.00 |
|
3 |
81382 |
HLA Class II typing, high resolution (ie,
alleles or allele groups); 1 locus (eg, HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1,
-DQA1, -DPB1, or -DPA1), each |
2,000.00 |
|
4 |
81251 |
GBA (glucosidase, beta, acid) (eg, Gaucher
disease) gene analysis, common variants (eg, N370S, 84GG, L444P,
IVS2+1G>A) |
500.00 |
|
5 |
81375 |
HLA Class II typing, low resolution (eg, antigen
equivalents); HLA-DRB1/3/4/5 and -DQB1 |
1,000.00 |
|
6 |
81374 |
HLA Class I typing, low resolution (eg, antigen
equivalents); 1 antigen equivalent (eg, B*27), each |
350.00 |
|
7 |
81228 |
Cytogenomic constitutional (genome-wide)
microarray analysis; interrogation of genomic regions for copy number
variants (eg, Bacterial Artificial Chromosome [BAC] or oligo-based
comparative genomic hybridization [CGH] microarray analysis) |
4,800.00 |
|
8 |
89240 |
Unlisted miscellaneous pathology test |
310.00 |
|
9 |
81331 |
SNRPN/UBE3A (small nuclear ribonucleoprotein
polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome
and/or Angelman syndrome), methylation analysis |
440.00 |
|
10 |
2003074 |
SIALIDOSIS |
1,350.00 |
|
11 |
2006046 |
BACTERIAL ANTIGEN (CSF) |
0.00 |
|
12 |
2001446 |
Combine Pitutary Adrenal Tests,Female |
0.00 |
|
13 |
2001447 |
Combine Pitutary Adrenal Tests,Female |
0.00 |
|
14 |
2001448 |
Combine Pitutary Adrenal Tests,Female |
0.00 |
|
15 |
2001443 |
Combine Pitutary Adrenal Tests,Female |
0.00 |
|
16 |
2001450 |
Combine Pitutary Adrenal Tests,Male |
0.00 |
|
17 |
2001453 |
Combine Pitutary Adrenal Tests,Male |
0.00 |
|
18 |
2001454 |
Combine Pitutary Adrenal Tests,Male |
0.00 |
|
19 |
2001455 |
Combine Pitutary Adrenal Tests,Male |
0.00 |
|
20 |
3010140 |
CBU MOLECULAR HLA TYPING |
2,000.00 |
|
21 |
3010130 |
REGISTRATION (CBU) |
1,000.00 |
|
22 |
3010110 |
UNRELATED CORD BLOOD DONATION |
0.00 |
|
23 |
3010135 |
PROCESSING & CRYOPRESERV OF CBU |
8,000.00 |
|
24 |
2004457 |
FOOD INTOLERANCE TEST |
3,000.00 gross = 2,400.00 NET |
|
25 |
81270-1 |
JAK2 (Janus kinase 2) (eg, myeloproliferative
disorder) gene analysis, p.Val617Phe (V617F) variant |
800.00 |
|
26 |
81270-2 |
JAK2 (Janus kinase 2) (eg, myeloproliferative
disorder) gene analysis, p.Val617Phe (V617F) variant |
1,289.00 |
|
27 |
81270-3 |
JAK2 (Janus kinase 2) (eg, myeloproliferative
disorder) gene analysis, p.Val617Phe (V617F) variant |
1,500.00 |
|
28 |
81270-4 |
JAK2 (Janus kinase 2) (eg, myeloproliferative
disorder) gene analysis, p.Val617Phe (V617F) variant |
2,363.00 |
|
29 |
81315 |
PML/RARalpha, (t(15;17)), (promyelocytic
leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia)
translocation analysis; common breakpoints (eg, intron 3 and intron 6),
qualitative or quantitative |
1,156.00 |
|
30 |
81315-1 |
PML/RARalpha, (t(15;17)), (promyelocytic
leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia)
translocation analysis; common breakpoints (eg, intron 3 and intron 6),
qualitative or quantitative |
605.00 |
|
31 |
81405 |
Molecular pathology procedure, Level 6 (eg,
analysis of 6-10 exons by DNA sequence analysis, mutation scanning or
duplication/deletion variants of 11-25 exons) CYP21A2 (cytochrome P450,
family 21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform,
congenital adrenal hyperplasia), full gene sequence FKTN (fukutin) (eg,
limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence MPZ
(myelin protein zero) (eg, Charcot-Marie-Tooth), full gene sequence NEFL
(neurofilament, light polypeptide) (eg, Charcot-Marie-Tooth), full gene
sequence RET (ret proto-oncogene) (eg, multiple endocrine neoplasia, type 2A
and familial medullary thyroid carcinoma), targeted sequence analysis (eg,
exons 10, 11, 13-16) SDHB (succinate dehydrogenase complex, subunit B, iron
sulfur) (eg, hereditary paraganglioma), full gene sequence TGFBR1
(transforming growth factor, beta receptor 1) (eg, Marfan syndrome), full
gene sequence TGFBR2 (transforming growth factor, beta receptor 2) (eg,
Marfan syndrome), full gene sequence THRB (thyroid hormone receptor, beta)
(eg, thyroid hormone resistance, thyroid hormone beta receptor deficiency),
full gene sequence or targeted sequence analysis of >5 exons TP53 (tumor
protein 53) (eg, Li-Fraumeni syndrome, tumor samples), full gene sequence or
targeted sequence analysis of >5 exons VWF (von Willebrand factor) (eg,
von Willebrand disease type 2N), targeted sequence analysis (eg, exons 18-20,
23-25) |
1,278.00 |
|
32 |
New |
Chimerism testing |
2,330.00 |
|
33 |
New |
Neopterin |
375.00 |
|
34 |
New |
AMPD1 Gene Mutations |
1,430.00 |
|
35 |
New |
West-Nile-Virus IgM spec. abs. (quant.) |
332.00 |
|
36 |
New |
West-Nile-Virus IgG spec. abs. (qual.) |
332.00 |
|
37 |
New |
West-Nile-Virus IgG spec. abs. (quant.) |
332.00 |
|
38 |
New |
Polycyctic Liver Disease (PCLD)NGS. |
6,830.00 |
|
39 |
2082735 |
JC Virus PCR,CSF |
405.00 |
|
40 |
2082736 |
Copper Urine,24 Hrs |
125.00 |
|
41 |
2082737 |
Citrate Urine,24 Hrs |
161.00 |
|
42 |
2082738 |
HLA-DQ2/8(Celiac Disease) |
530.00 |
|
43 |
2082739 |
BRAF V600E Mutation |
1,513.00 |
|
44 |
2082740 |
Slides for second opinion |
250.00 |
|
45 |
2082741 |
Retina Abs |
179.00 |
|
46 |
2082742 |
Cholestenol Level |
73.00 |
|
47 |
2082743 |
Phospholipase A2 Receptor Abs Qual |
247.00 |
|
48 |
2082744 |
Phospholipase A2 Receptor Abs Quan |
247.00 |
|
49 |
2082745 |
Cimzia Level & Abs |
2,021.00 |
|
50 |
2082746 |
Neopterin, Urine |
339.00 |
|
51 |
2082747 |
PEX16/PC Gene |
5,416.00 |
|
52 |
2082748 |
Inhibitor Screening |
238.00 |
|
53 |
2082749 |
HEV abs. (IgG/immunoblot) |
185.00 |
|
54 |
2082750 |
HEV abs. (IgM/immunoblot) |
185.00 |
|
55 |
2082751 |
Myelin Oligodendrocyte Glycoprotien Abs |
269.00 |
|
56 |
2082752 |
CA 125 Body Fluids |
185.00 |
|
57 |
2082753 |
Carnitine,Total (Serum) |
206.00 |
|
58 |
2082754 |
Breast & Ovarian Cancer 1 &2 |
4,380.00 |
|
59 |
2082755 |
Zinc Transporter 8 Abs |
233.00 |
|
60 |
2082758 |
Familial Mutation Testing (one mutation,
sequencing) |
980.00 |
|
61 |
2082759 |
17-OH Pregnenolone, 24 Hrs Urine |
364.00 |
|
62 |
2082760 |
Mutational Analysis CML(Chronic Myeloid
Leukaemia) |
1,509.00 |
|
63 |
2090001 |
Fatty Acid Profile, Comprehensive (C8-C26) |
200.00 |
|
64 |
2090002 |
Glucopsychosine, Blood Spot |
1,820.00 |
|
65 |
2090003 |
Ceramide Trihexosides and Sulfatides, Urine |
2,366.00 |
|
66 |
2090004 |
Tartrate Resistant Acid Phosphatase (TRAP) |
1,915.00 |
|
67 |
2090005 |
Chitotriosidase |
427.00 |
|
68 |
2090006 |
M GLUR 5 Receptor Abs,Serum |
256.00 |
|
69 |
2090007 |
M GLUR 5 Receptor Abs,CSF |
176.00 |
|
70 |
2090008 |
SOX1 ABS,Serum |
206.00 |
|
71 |
2090009 |
SOX1 ABS,CSF |
126.00 |
|
72 |
2090010 |
GABA-B-Receptor 1 ABS,Serum |
184.00 |
|
73 |
2090011 |
GABA-B-Receptor 1 ABS,CSF |
104.00 |
|
74 |
2090012 |
Glycine Receptor Abs.IgG,Serum |
256.00 |
|
75 |
2090013 |
Glycine Receptor Abs.IgG,CSF |
176.00 |
|
76 |
2090014 |
Galactosemia (GALT) gene |
3,118.00 |
|
77 |
2090015 |
Oxalate ,Plasma |
182.00 |
|
78 |
2090016 |
Beta-Amyloid 42/40 Ratio, CSF |
8,498.00 |
|
79 |
81402-1 |
Molecular pathology procedure, Level 3 (eg, >
10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using
non-sequencing target variant analysis], immunoglobulin and T-cell receptor
gene rearrangements, duplication/deletion variants 1 exon) CYP21A2
(cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital
adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg,
IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L,
L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR
(receptor 1/progesterone receptor) ratio (eg, breast cancer) KIT (v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis),
common variants (eg, D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg,
familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L,
M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL
(myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR)
(eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L,
W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma),
gene rearrangement analysis, evaluation to detect abnormal clonal population |
980.00 |
|
80 |
81402-2 |
Molecular pathology procedure, Level 3 (eg, >
10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using
non-sequencing target variant analysis], immunoglobulin and T-cell receptor
gene rearrangements, duplication/deletion variants 1 exon) CYP21A2
(cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital
adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg,
IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L,
L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR
(receptor 1/progesterone receptor) ratio (eg, breast cancer) KIT (v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis),
common variants (eg, D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg,
familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L,
M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL
(myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR)
(eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L,
W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma),
gene rearrangement analysis, evaluation to detect abnormal clonal population |
1,928.00 |
|
81 |
81403 |
Molecular pathology procedure, Level 4 (eg, analysis of single exon by
DNA sequence analysis, analysis of > 10 amplicons using multiplex PCR in 2
or more independent reactions, mutation scanning or duplication/deletion
variants of 2-5 exons) ABL1 (c-abl oncogene 1, receptor tyrosine kinase) (eg,
acquired imatinib tyrosine kinase inhibitor resistance), variants in the
kinase domain DAZ/SRY (deleted in azoospermia and sex determining region Y)
(eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd) GJB1
(gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene
sequence JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12
sequence and exon 13 sequence, if performed KRAS (v-Ki-ras2 Kirsten rat
sarcoma viral oncogene) (eg, carcinoma), gene analysis, variant(s) in exon 2
MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor,
TPOR) (eg, myeloproliferative disorder), exon 10 sequence VHL (von
Hippel-Lindau tumor suppressor) (eg, von Hippel-Lindau familial cancer
syndrome), deletion/duplication analysis VWF (von Willebrand factor) (eg, von
Willebrand disease types 2A, 2B, 2M), targeted sequence analysis (eg, exon
28) |
980.00 |
|
82 |
84999-1 |
Unlisted chemistry procedure |
1,000.00 |
|
83 |
84999-2 |
Unlisted chemistry procedure |
1,293.00 |
|
84 |
84999-3 |
Unlisted chemistry procedure |
9,000.00 |
|
85 |
84999-4 |
Unlisted chemistry procedure |
12,500.00 |
|
86 |
86160-1 |
Complement; antigen, each component |
120.00 |
|
87 |
86160-2 |
Complement; antigen, each component |
210.00 |
|
88 |
86162-1 |
Complement; total hemolytic (CH50) |
184.00 |
|
89 |
86162-2 |
Complement; total hemolytic (CH50) |
268.00 |
|
90 |
82657-1 |
Enzyme activity in blood cells, cultured cells, or tissue, not
elsewhere specified; nonradioactive substrate, each specimen |
600.00 |
|
91 |
82657-2 |
Enzyme activity in blood cells, cultured cells, or tissue, not
elsewhere specified; nonradioactive substrate, each specimen |
934.00 |
|
92 |
87797-1 |
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise
specified; direct probe technique, each organism |
214.00 |
|
93 |
87797-2 |
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise
specified; direct probe technique, each organism |
222.00 |
©2020 The Supreme
Legislation Committee in the Emirate of Dubai
[1]Every effort
has been made to produce an accurate and complete English version of this
legislation. However, for the purpose of its interpretation and application,
reference must be made to the original Arabic text. In case of conflict, the
Arabic text will prevail.